PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.53), $0.22 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $217.1 million versus the consensus estimate of $178.9 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• HSBC Upgrades Synopsys (SNPS) to Buy, 'Transforming into an AI beneficiary'
• Bernstein sees downside risk to Apple's December quarter results